1 / 11

A randomized trial of glutamine and antioxidants in critically ill patients

A randomized trial of glutamine and antioxidants in critically ill patients. Greg Gaines PA-S. Outline. Glutamine Depletion Methods Results Conclusion. Glutamine Depletion. In critically ill patients there is rapid depletion of plasma glutamine levels Associated with increased mortality

petra
Télécharger la présentation

A randomized trial of glutamine and antioxidants in critically ill patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A randomized trial of glutamine and antioxidants in critically ill patients Greg Gaines PA-S

  2. Outline • Glutamine Depletion • Methods • Results • Conclusion

  3. Glutamine Depletion • In critically ill patients there is rapid depletion of plasma glutamine levels • Associated with increased mortality • Hypothesized that critically ill patients with organ dysfunction would be most likely to have low plasma glutamine levels

  4. Trial objective • Evaluate the effect of glutamine and antioxidant supplementation • Hypothesis: Supplementation will reduce 28 day mortality • P<0.044 would indicate statistical significance

  5. Methods • Blinded 2-by-2 study • Patient Population • 1218 critically ill adults • Multiorgan failure • Mechanical ventilation • Location of the trial • 40 different ICUs • United States, Canada, Europe • April 2005 - December 2011

  6. Methods • Patients were given • Glutamine (303) • Antioxidants (308) • Both (310) • Placebo (302) • Administration • Within 24 of admission • Intravenously and enterally • For a maximum of 28, until discharge, or death

  7. results • 70.9% of enteral study supplements • 89.1% of IV study supplements • 28-day mortality: 29.8% (95% CI, 27.2-32.5) • Glutamine had increased mortality trend (32.4% vs. 27.2%) • Antioxidants had no difference • Glutamine and Antioxidants together had no significant difference • 6 month mortality • Significantly increase with patients who received glutamine • Discharge median time from the ICU was significantly increased • Antioxidant had no results

  8. conclusion • Glutamine • Nonsignificant 28-day mortality increase • Significant increase in in-hospital and 6-month mortality • No other effect • Unknown how it may cause harm • Antioxidant • No benefit or harm • Study population, dose or administration

  9. Reasons for Glutamine discrepancy • This is a larger, more methodical trial than those done in the past • These patients received the highest dose of glutamine • Both intravenous and enteral supplementation • Targeted critically ill patients, the majority or whom were in shock • Supplementation was initiated within 24 hours of admission • Most received enteral nutrition • Substudy of patients did not consistently find a deficiency of glutamine in 66 patients.

  10. My assessment of the study • Too many variables • Remove the antioxidants from the study • Consider finding what percentage of those, if any in the study actually had glutamine deficiency. • Consider a study with subjects that have been determined to have glutamine deficiency.

  11. Works Cited • Hayland MD, Daren, , et al. "A Randomized Trial of Glutamine." New England Journal of Medicine. 368.16 (2013): 1489-1497. Print. <http://phdres.caregate.net/jclub-articles/Husain..050713.pdf>.

More Related